Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


08. December 2020 | 10:02 CET

Nio, Desert Gold, Bayer - Don't miss these opportunities!

  • Investments
Photo credits: pixabay.com

If in March 2020 before the first lockdown due to the Corona pandemic began you had consistently filled your portfolio with shares, primarily with papers from the technology sector, you would be happy to see growth rates of several 100%. However, one does not earn money on the stock market with ifs and buts. The good news is that there are always new opportunities that you can take advantage of without any ifs and buts.

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Gold on the road to recovery

Gold maintained its essential support zone at USD 1,800.00 last week and is currently trading at USD 1,869.00. The correction, which has been underway since August, did not stop at gold mine stocks either. Especially in this sector, there are good opportunities at the moment to invest favourably in promising companies which, with a full pipeline, should be among the winners in the next upswing. One of these exciting Companies is Desert Gold, which focuses on gold mining in the West African country of Mali. Mali is rich in mineral resources and the third-largest gold producer in Africa. Particular focus is currently on the 410 sq km SMSZ project, which extends over approximately 38 km of the productive Senegal-Mali shear zone.

A project with great potential

Last week marked the long-awaited start of the most extensive exploration program in the Company's history. According to management, the SMSZ project in western Mali is planned to drill over 20,000 metres and additional drilling for a further 20,000 metres if required. The SMSZ Project is one of the largest gold exploration projects in West Africa. Along strike, the main Desert Gold project is connected to five significant mines to the north and south. These include mines of the big players such as B2 Gold, Barrick Gold and Allied Gold.

Optimistic outlook

Desert Gold's Chairman, Jared Scharf, is optimistic about the future: "I'm very pleased to begin this work season fully funded with a highly experienced operating team on the ground. The SMSZ project is one of the largest gold exploration projects in West Africa and is ideally situated along the prolific Senegal Mali shear zone. This project will be our main focus this year as it hosts a myriad of highly prospective, advanced and early-stage targets in the right regional setting. Looking forward into 2021, we expect consistent news flow throughout the year as results are published while we continue developing new and existing targets."

This positive news could also be the starting signal for the share price. After a high at CAD 0.35, Desert Gold's share price corrected to CAD 0.12. After the announcement last week, the share price was able to move back towards CAD 0.20. With further positive news flow, enormous fantasy is in the paper of Desert Gold.

On the right track

The latest news from Bayer AG was consistently positive and gives hope for a comeback of the former DAX leader. Only the ongoing legal dispute regarding a settlement in the glyphosate affair puts everything else in the shade. The Leverkusen-based Company is strengthening its pharmaceuticals business with the US biotech Company Atara Biotherapeutics. Through this collaboration, the Group is entering the field of so-called CAR-T cell therapies and, among other things, securing access to a promising cancer immunotherapy from Atara.

Depending on how particular development, approval and marketing objectives are met, Atara may receive payments totalling USD 610 million. The analysts of Deutsche Bank acknowledge the efforts of Bayer's management in recent weeks and confirm their recommendation to 'buy' the share with a price target of EUR 62.00.

Where is the journey heading?

The Chinese electric carmaker Nio has recently had to make some significant corrections. The stock market star that was celebrated only a short time ago lost more than 20% of its value. The reasons once again lie in the still smouldering conflict between the USA and China. Last week, the House of Representatives passed a bill that should make the delisting of the Chinese stock market giants like Alibaba and Nio possible.

Should this be a sabre-rattling of the still active government around the outgoing President Donald Trump, the Americans would once again shoot themselves in the knee. The delistings would lead to massive capital outflows from the United States. Currently, Nio is fighting with the critical support at the equivalent of EUR 35.00. The fundamental outlook remains positive. We consider the occurrence of a delisting very unlikely.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read